PsychedelicNewsBreaks Archive - Page 35 of 67

MondayNov 29, 2021 11:48 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved key milestones. The milestones were outlined in the agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. Based on the agreement, 31,721.5 class B common shares of the company will be issued to Adelia shareholders as a result of relevant milestones being met. Adelia develops medicinal psychedelics designed to provide improved dosing efficacy and therapeutic indices that address unmet medical needs. The company’s primary focus is on the…

WednesdayNov 24, 2021 12:21 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Looking to Change Narrative in Treating Fibromyalgia, Chronic Pain

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is looking to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients. To achieve this, the company is relying on the guidance of its scientific advisory board (“SAB”) as well as research-based work conducted in partnership with the University of Michigan (“U-M”). “According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people). Unfortunately, despite the disease afflicting millions, researchers have not yet…

TuesdayNov 23, 2021 10:29 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. According to the update, the program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. “It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Dr. Alex Belser, chief clinical officer of Cybin.…

ThursdayNov 18, 2021 11:46 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CEO Discusses Blockbuster Drug Potential on MidasLetter Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent MidasLetter Live podcast. Mydecine’s CEO and Chairman Joshua Bartch joined the program to provide an overview of the company and the science behind its psychedelic compounds. “What we are showing in the efficacy rates that are coming out of that study are over three to five times what’s currently available of Chantix or a nicotine patch with a much safer drug,” Bartch said in discussing clinical trials for smoking cessation using…

ThursdayNov 18, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Unveils First-of-Its-Kind Family Support & Education Program

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that its chain of Ketamine Wellness Clinics (“KWC”) will be offering the industry’s first support and education program designed to support the family and loved ones of its patients. KWC, the country’s largest chain of wellness centers that provide ketamine treatments, launched its Family Support & Education program today; the free program is designed by medical professionals to help families, significant others and loved ones provide valuable support to patients who choose ketamine infusion treatments. In announcing the program,…

TuesdayNov 16, 2021 12:48 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) CEO Featured in Latest Episode of ‘Bell2Bell’ Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation, was featured in the latest episode of The Bell2Bell Podcast. Among other highlights of the interview, Delic CEO Matt Stang discussed the company’s network of businesses and the impact psychedelic research is having on the treatment of mental health. “We feel that the time is right now. The mental health crisis is sweeping not only this country but the world,” Delic Holdings CEO Matt Stang stated in the interview. “Last year, in America, we had four-times the…

TuesdayNov 16, 2021 9:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to the chief scientific advisor. She brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis.…

MondayNov 15, 2021 12:45 pm

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Featured in Equity Research Report

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs and clinical development, including synthetic ibogaine, for which it is planning a preclinical study with its research partner to initially conduct cardiac and neurological screens with data and potentially move into behavioral studies. In addition, the company plans to schedule a pre-IND meeting for its…

MondayNov 15, 2021 12:19 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Committed to Making Psychedelic Wellness Accessible to the Masses

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is well positioned to capitalize on the psychedelic industry’s continued growth trajectory. “The company owns and operates a self-sustaining ecosystem of businesses in the psychedelic space consisting of media, science and health business verticals. Delic has been particularly active on the mergers and acquisitions front over the last several months in a bid to further broaden the company’s business horizons,” reads a recent article. In March, the company acquired the brand and IP of Homestead, a legacy counterculture distributor of psychedelic media and creator of one of the first…

MondayNov 15, 2021 11:02 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has released its unaudited second-quarter results and announced a conference call to review the report. The report covers the period ended Sept. 30, 2021. Highlights in the report included the company’s announcement of preclinical data for its novel deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder and alcohol use disorder. The company has also been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab and has received FDA approval to proceed with a company-sponsored…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

PsychedelicNewsBreaks